Concepedia

Alex F. Herrera

AF

141

Publications

10.2K

Citations

45

H-Index

2006

Active since

Affiliations

City of Hope(Current)

City Of Hope National Medical Center

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Alex F. Herrera is an author at City of Hope specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

2006–2025

141

Publications

141

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.2K citations

, , +9

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 741 citations · Full text

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Caron A. Jacobson, Bradley D. Hunter, Robert Redd et al. · Journal of Clinical Oncology · 2020 · 332 citations · Full text

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett et al. · Blood · 2017 · 317 citations · Full text

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu, Michael Dickinson, Javier Muñoz et al. · Nature Medicine · 2022 · 266 citations · Full text

Rows per page

1–5 of 141